Director, Pricing and Contracting
- Employer
- Intellia Therapeutics
- Location
- Cambridge, MA
- Start date
- Jan 29, 2025
View more categoriesView less categories
- Discipline
- Administration, Finance, Clinical, Marketing, Market Access, Health Economics & Outcomes Research
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Genetown, Best Places to Work
Job Details
Why Join Intellia?
Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.
We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.
How You Will Achieve More with Intellia:
As the Director, Pricing & Contracting at Intellia, you will play a pivotal role in shaping our pricing, contracting, and market access strategies as we bring our gene editing therapies to market. This role requires a visionary leader with deep experience in innovative pricing models, value-based contracting, and building the foundational capabilities necessary for a successful therapy launch. The ideal candidate will have a track record of success in developing and executing pricing and contracting strategies within the biotech or pharmaceutical industry, ideally with experience in specialty therapies, biologics, or cell & gene therapy. Level will be determined based on relevant experience and will report to the VP, Market Access & Patient Services.
Responsibilities:
Pricing Strategy Development:
Lead the development of innovative and flexible pricing strategies tailored for the gene editing market, ensuring alignment with the therapy’s clinical and economic value.
Support the team’s understanding of coding and other payment requisites for launch.
Develop strategies that address unique gene editing market challenges, including affordability, payer acceptance, and access equity.
Leverage data-driven insights, competitive landscape analysis, and pricing research to inform short- and long-term pricing decisions.
Value-Based Contracting:
Design and implement value-based contracts (as required) that align our gene editing therapies’ value with real-world outcomes.
Collaborate with payers, providers, and other stakeholders to create customized contracting solutions that de-risk investments and enhance patient access.
Evaluate, and implement as applicable, innovative reimbursement models, such as outcomes-based, indication-based, and milestone-based pricing agreements, to promote sustainable, value-driven healthcare solutions.
Payer and Provider Engagement:
As needed in partnership with account management, build and strengthen relationships with key payers and providers to enhance understanding and adoption of our therapies through innovative contracting or risk-sharing models.
Articulate the clinical and economic value of our gene editing therapies in collaboration with medical, commercial, and market access teams.
Proactively engage with health economics and outcomes research (HEOR) and medical teams to develop evidence-based narratives that support value-based discussions and financial arrangements with payers and providers.
Market Access & Launch Readiness:
Develop a launch framework for our pipeline of gene editing therapies, ensuring market access readiness through robust pricing, reimbursement, and contracting strategies.
Work closely with the commercial, medical, legal, and regulatory teams to support the successful launch of gene editing therapies by reducing provider reimbursement barriers.
Build and refine processes and systems to enable scalable contracting operations as we expand our portfolio.
Develop and enable reimbursement of our therapies including coding and all provider-facing office support and education materials.
Identify and manage 3rd party vendor for government pricing management; ensure compliance and accurate GTN forecasting.
Capability Building & Team Development:
Establish and lead a high-performing Pricing & Contracting capability to deliver our strategic goals. Potential for 1 direct report.
Foster an environment of innovation, knowledge sharing, and continuous improvement.
Develop and implement best practices, tools, and frameworks that will serve as a foundation for current and future product launches.
About You:
Demonstrated experience developing innovative pricing and contracting strategies, including value-based agreements.
Strong understanding of the payer landscape, pricing research methodologies, and market access dynamics in gene therapy or specialty as well as expertise in key US reimbursement dynamics such as buy and bill models, government pricing including 340B.
Proven ability to collaborate cross-functionally and influence senior-level decision-making.
Excellent communication, negotiation, and analytical skills.
Experience launching novel therapies with a focus on establishing market access & reimbursement within provider offices and value-based care models.
Strong background in health economics, outcomes research, or market access strategy preferred.
Ability to work effectively in a fast-paced, growth-oriented environment with a commitment to addressing the unique challenges of gene editing therapies.
Bachelor’s degree required; advanced degree in Business, Economics, Finance, or a related field preferred.
6-8+ years in pharmaceutical or biotech industry, with a minimum of 5 years in pricing, market access, or contracting, preferably in specialty or gene therapies.
#LI-Hybrid
#LI-SV1
Covid-19 Vaccination Policy:All Intellia employees, regardless of work location, are expected to follow all applicable federal, state, and local public health regulations and guidelines, and are strongly encouraged to follow all public health recommendations, including being vaccinated for COVID-19.
EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Company
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
- Website
- http://intelliatx.com/
- Phone
- (857) 285-6200
- Location
-
40 Erie Street
Cambridge
Massachusetts
02139
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert